JCIA
CTMX icon

Jackson Creek Investment Advisors’s CytomX Therapeutics CTMX Stock Holding History

Jackson Creek Investment Advisors’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-80,367
Closed -$526K – 334
2020
Q4 		$526K Sell
80,367
-137
-0.2% -$979 0.21% 223
2020
Q3 		$535K Buy
+80,504
New +$597K 0.24% 221

Other funds holding CTMX

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Jackson Creek Investment Advisors's CTMX Position: Q1 2021 in Review

Jackson Creek Investment Advisors sold out of CytomX Therapeutics (CTMX) in Q1 2021, closing a stake of 80,367 shares — an estimated $526K sold.

Jackson Creek Investment Advisors first reported a position in CTMX in Q3 2020 and held it in 2 quarters. The position peaked at $535K in Q3 2020. 126 funds tracked by Wall St. Rank hold CTMX as of Q1 2021.

  • Jackson Creek Investment Advisors reported no remaining CytomX Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Jackson Creek Investment Advisors sold 80,367 CytomX Therapeutics shares in Q1 2021, an estimated $526K.
  • Jackson Creek Investment Advisors first reported a position in CytomX Therapeutics in Q3 2020 and held it in 2 quarters.
  • Jackson Creek Investment Advisors's CytomX Therapeutics position peaked at $535K in Q3 2020.
  • 126 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2021.

Based on Jackson Creek Investment Advisors's 13F filing for Q1 2021, filed 27 May 2021.